Abstract

  Objective : The aim of this study was to evaluate the efficacy and safety, comorbidity, and incidental carcinoma occurrence associated with Holmium laser enucleation of the prostate (HoLEP) for benign prostatic hyperplasia (BPH) patients.
  Methods : All 363 patients were assessed based on the International Prostate Symptom Score (IPSS), Quality of Life index (QOL index), peak flow rate (Qmax), voided volume, and residual volume. These parameters were measured preoperatively and 1 week, 3 months and 1 year postoperatively. Perioperative comorbidity and enucleated specimens were examined.
  Results : All procedures were successfully performed without major complications. The median operation time and enucleation weight were 105 minutes and 41 grams, respectively. IPSS, QOL index, Qmax, voided volume, and residual volume significantly improved postoperatively. Twenty-four (6.6%) patients were diagnosed with incidental carcinoma. Thereafter, 5 (1.3%) patients were newly diagnosed with de novo prostate cancer.
  Conclusion : Our results demonstrate that HoLEP is a safe and effective procedure for BPH patients.